跳转至内容
Merck
CN
  • Sterically stabilized polymeric nanoparticles with a combinatorial approach for multi drug resistant cancer: in vitro and in vivo investigations.

Sterically stabilized polymeric nanoparticles with a combinatorial approach for multi drug resistant cancer: in vitro and in vivo investigations.

International journal of pharmaceutics (2014-12-03)
Sobiya Zafar, Lalit Mohan Negi, Anita Kamra Verma, Vijay Kumar, Aakriti Tyagi, Pratibha Singh, Zeenat Iqbal, Sushama Talegaonkar
摘要

The present work describes the preparation of sterically stabilize polymeric nanoparticles of mitoxantrone dihydrochloride (MTO) along with an efflux transporter (Pgp/BCRP) inhibitor that enhance the circulation time of nanoparticles and simultaneously surmount the problem of multidrug resistance (MDR). Mitoxantrone dihydrochloride being hydrophilic in nature had very low entrapment efficiency (%E.E.), thus in order to further enhance the lipophilicity and the %E.E., it was complexed with sodium deoxycholate (SDC) and this MTO-SDC-complex was used to formulate nanoparticles with/without Pgp/BCRP inhibitor by nanoprecipitation technique and was characterized for various in vitro and in vivo attributes. In vitro cell line studies were conducted on MCF7, A2780(p) and A2780(adr) cells. Furthermore, the targeting potential of hyaluronic acid (HA) coated nanoparticles for CD44 receptors was investigated using the MCF7 cell line. A reduction in the IC50 value observed with the inhibitor loaded nanoparticles in different cell lines indicated the BCRP/Pgp inhibiting ability of the formulated nanoparticles. The reduced macrophage uptake and the increased residence time in blood demonstrated the long circulating behaviour of the nanoparticles. The enhanced cellular uptake of HA coated nanoparticles in MCF7 cells revealed their targeting potential. The HA coated nanoparticles along with efflux transporter inhibitor exhibits a great potential for targeted chemotherapy in CD44 overexpressing MDR breast cancer.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
溴化十六烷基三甲铵, ≥98%
Sigma-Aldrich
槲皮素, ≥95% (HPLC), solid
Sigma-Aldrich
脱氧胆酸钠, BioXtra, ≥98.0% (dry matter, NT)
Sigma-Aldrich
溴化十六烷基三甲铵, Molecular Biology, ≥99%
Sigma-Aldrich
脱氧胆酸钠, ≥97% (titration)
Sigma-Aldrich
溴化十六烷基三甲铵, BioXtra, ≥99%
SAFC
脱氧胆酸钠
Sigma-Aldrich
三辛胺, 98%
Sigma-Aldrich
香豆素 6, 98%
Supelco
槲皮素, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
溴化十六烷基三甲铵, BioUltra, Molecular Biology, ≥99.0% (AT)
USP
槲皮素, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
溴化十六烷基三甲铵, ≥96.0% (AT)
Sigma-Aldrich
检皮素, ≥95%
Sigma-Aldrich
甲基三氧苯 (VII), Re 71.0-76.0 %
Sigma-Aldrich
米托蒽醌 二盐酸盐, ≥97% (HPLC)
USP
鲸蜡烷三甲基溴化铵, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
香豆素 6, ≥99%
Supelco
检皮素, analytical standard
米托蒽醌 盐酸盐, European Pharmacopoeia (EP) Reference Standard
Supelco
溴化十六烷基三甲铵, analytical standard
Supelco
溴化十六烷基三甲铵, suitable for ion pair chromatography, LiChropur
Sigma-Aldrich
脱氧胆酸钠, Vetec, reagent grade, ≥97%
Sigma-Aldrich
溴化十六烷基三甲铵, Vetec, reagent grade, 96%